GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adaptive Biotechnologies Corp (FRA:1HM) » Definitions » Notes Receivable

Adaptive Biotechnologies (FRA:1HM) Notes Receivable : €0.0 Mil (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Adaptive Biotechnologies Notes Receivable?

Adaptive Biotechnologies's Notes Receivable for the quarter that ended in Mar. 2024 was €0.0 Mil.


Adaptive Biotechnologies Notes Receivable Historical Data

The historical data trend for Adaptive Biotechnologies's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adaptive Biotechnologies Notes Receivable Chart

Adaptive Biotechnologies Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Notes Receivable
Get a 7-Day Free Trial - - - - -

Adaptive Biotechnologies Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Adaptive Biotechnologies Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Adaptive Biotechnologies Notes Receivable Related Terms

Thank you for viewing the detailed overview of Adaptive Biotechnologies's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Adaptive Biotechnologies (FRA:1HM) Business Description

Traded in Other Exchanges
Address
1165 Eastlake Avenue East, Seattle, WA, USA, 98109
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease ("MRD") in patients with multiple myeloma ("MM"), B cell acute lymphoblastic leukemia ("ALL") and chronic lymphocytic leukemia ("CLL") and is also available as a CLIA-validated laboratory developed test ("LDT") for patients with other lymphoid cancers, including diffuse large B-cell lymphoma ("DLBCL").

Adaptive Biotechnologies (FRA:1HM) Headlines

No Headlines